WHO/UNICEF Integrated Management of Childhood Illness (IMCI) and Child Health Redesign

Shamim Qazi, Geneva



IMCI Technical Updates

- 2005
- 2008
- 2012
- 2019 and implementation research

Child Health Redesign

IMCI Updates...do we need them?



New research results are emerging from randomized, controlled trials

Recommendations are being regularly reviewed and updated

Changing disease epidemiology- neonatal deaths are gaining increasing prominence in total U5 deaths

New ways of IMCI training need to be introduced

2005 IMCI Updates

The updates covered six areas:

- Antibiotic treatment of severe and nonsevere pneumonia & inclusion of wheeze
- Low osmolarity ORS, Zinc and antibiotic treatment for bloody diarrhoea
- Treatment of malaria with ACTs
- Treatment of ear infections with topical quinolones
- Infant and young child feeding
- Treatment of helminthiasis



2008 IMCI Updates

The updates covered mainly sick young infant

- New sections on the management of illness in the first week of a child's life.
- Young infant module for IMCI training
- Included HIV section in high HIV settings.

Note: Training modules were updated only in ICATT





2012 IMCI Updates

Changes in Assessment and Management of Children aged 2 months up to 5 years

- Check general danger signs
- Cough or difficult breathing
- Diarrhoea
- Fever/measles
- Ear problem
- Malnutrition
- Anaemia
- HIV infection

IMCI Update 2019

Young infant up to 2 months of age

Neonatal Infections burden



WHO AMANHI study, Lancet GH 2018

Treatment of Newborn Infections

Management of neonatal infections

- Initial diagnosis is based on clinical signs
- Treatment is IV/IM antibiotics and supportive care in a hospital
- Only 25% of newborns with possible serious infection receive hospital treatment in high-mortality settings

AFRINEST & SATT studies (2010-2013): WHO/MCA led research

• To find deliverable, effective treatment for newborns with signs of severe infection where referral is not possible

Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial

A (ricen Neonabal Sepais Trial (A FBNEST) group, Antoinette Tubefu, A drien Latengein, Sergen Ygeime, Cyrille ngmenn, Feblen Exemed, Febr Ghare, Adejumakel dowu Ayede, A degate Ghadegesin Falede, Ebuneke wa A Adejuyigbe, Chineme Henry Anyotosiu, Robinson D Wammande, Gara L Ejembi, William N Ogela, Lu Gran, Simon Causens

AFRINEST (DRC, Kenya, Nigeria) Lancet 2015

Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial

A (rison Neonal al Sepais Trial (AF RINEST) group A risolnettic Tshefu, A drient, okangalas, Serge Ngalma, Cyrl Eingmann, Fabian Esamai, Peter Ghang A dejumak eldowu Ayeda, A degok e Goodegevin Falade, Ebund uwa A A dejuyigba, Chinemet Ferry Anyabolu, Robinson O Wammanda, Charo L Ejembi, W Ham N Ogala, Lu Gram, Simon Cousers

AFRINEST (DRC, Kenya, Nigeria) Lancet 2015

Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial

A bdullah H Baqui, Samirk Saho, A S M Newshad Uddin Ahmed, Mahammad Shahidullah, (fathar Quesen; Daniel E Ruh, A K M Samuszaman, WashAhmed, S M Shahmawar Bin Tablo, Dipat K Milro, Nazma Begum, Matauda Mam, Ar∮ Mahmud, Mohammad Hefrur Rahman, Manun I bre Moin, Luke C Mullany, Simon Couseus, Shams El Ar∮een, Shephen Wali, Neol Brandeo, Mathuram Santosham, Robert E Bladi, for the Trojahmmo Saudy Group in Bangladesh^a

SATT Bangladesh Lancet Global Health 2015

Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial

Fatima Mir, Imran Nisar, Shiyam S Tikmani, Benazir Baloch, Sadia Shakoor, Fyezah Jehan, Imran Ahmed, Simon Cousens, Anita K M Zaidi

SATT Pakistan Lancet Global Health 2016

WHO guideline 2015

GUIDELINE Managing possible serious bacterial infection in young infants when referral is not feasible

Fast breathing as the only sign of illness (7-59d age) should be treated with oral amoxicillin for 7 days.

Facilitate referral of all other babies with clinical signs of severe infection to a hospital.

If referral is not feasible, outpatient treatment with twice daily oral amoxicillin for 7 days and injection gentamicin for 2 or 7 days.

http://apps.who.int/iris/bitstream/10665/181426/1/9789241509268_eng.pdf?ua=1

IMCI algorithm revised



Critically ill young infants for whom referral is not accepted by families after best efforts should be treated with once daily injectable gentamicin plus at least twice daily injection ampicillin for 7 days

New implementation strategy

Improved identification of infants with PSBI by families and CHWs

Treatment of fast breathing in 7-59 day olds with oral antibiotics at first level health facilities

Improved referral to hospital for other cases of PSBI

If referral is not possible, provided outpatient treatment at first level health facilities

WHO led Implementation research

AFRINEST & SATT were implemented in 3 million population, but not implemented by the health system

Policy guideline was available in India and Ethiopia but implementation was challenging

Some countries wanted more implementation experience before making a policy change

Implementation research as a BRIDGE to full-scale implementation

Issues with scale-up of this intervention

High risk population: severe neonatal infection

- Up to 15% mortality without treatment
- At least 2% mortality even with treatment

Complex intervention: injectable + oral antibiotics

- India ICMR Study: Few workers actually treated young infants
- India ANM guideline: Hardly any ANM treated young infants
- Ethiopia HEW guideline: low treatment rates for young infants

ESSENTIAL to have technical back up and support in early implementation phase

Steps in Implementation Research

Orientation and Policy dialogue at country level

Informed decisions on treatment choices for early implementation in selected sites

Establishment of early implementation sites & Technical Support Units (TSU) [Bangladesh – two sites; Democratic Republic of Congo – one site; Ethiopia – two sites; Malawi – one site; Nigeria – two sites; India – four sites; Pakistan – one site]

Building capacity and creating a learning platform (TSU)

Implementation, supervision, and monitoring

Child Health Redesign



IMNCI Strategic Review Conclusions and Recommendations

Benefits of IMNCI in design and impact	
Positive effects on health worker practices and quality of care.	Integrated Management of Childhood Illness
15% reduction in child mortality* when fully implemented in health facilities and communities.	Chart Booklet
IMNCI is perceived as holistic and child-centred .	<i>"IMNCI is very relevant for the country. It is a complete holistic module with child health, development, newborn, etc. Nothing needs to be taken out."</i>
Simple, comprehensive and targeted the major causes of mortality	- Policymaker (Myanmar)

* Cochrane review on IMCI (2016)

Conclusions and Recommendations– Strategic Review

Global fragmentation of child health strategies undermined programming and limited impact.

Need for systematic evidence generation, capture and integration into policy and programming.

Accountability for corresponding clear programme targets and strong monitoring.

Strategies sufficiently tailored to country context, and with improved end-user designed tools.

Child health SDG goals will not be met without adequate funding and delivery to marginalized populations

Why child health redesign?

New global architecture: MDGs → SDGs, Universal Health Coverage (UHC), revitalized PHC & UN secretary General's Global MNCH Strategy

Shifting epidemiology:

- <u>Age</u> and <u>structure</u>: shifting age in mortality and morbidly patterns
- Aetiological <u>causes</u>: changing burden and emerging priorities
- Geospatial distribution of morbidity and mortality

Greater emphasis on health determinants requiring more community engagement and interventions beyond the health sector*

*Kuruvilla S et al. Success factors for reducing maternal and child mortality. Bull WHO 2014

Why Child Health Redesign? (2)

Expanded scientific evidence on the best clinical interventions and delivery strategies.

New technologies and innovations:

• new vaccines, diagnostics and treatment innovations, mHealth, eHealth, ...

Demand for content that responds to the changing country context:

- harmonized and optimized content
- **<u>flexible</u>** and **<u>adaptable</u>** to country contexts

Conceptualizing Redesign

Taking a **life course approach** to child health in the context of SDGs

• Redefine and reposition "the child"



Refocus and prioritize the child survival agenda

• leading causes of mortality, target age group

Define, prioritize and address emerging child health priorities

Conceptualizing Redesign (2)

Define, prioritize, and mainstream thrive agenda

• What ? When? Where?

Harmonize and mainstream "Promote", "Prevent" and "Treat" across all levels of care

Optimize guidance to improve flexibility and adaptability

Child Health Redesign Conceptual Framework



Goal=Optimally healthy, appropriately educated child socially prepared for adulthood ←Age appropriate Nutrition Interventions→







Thank you